{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:33:31Z","timestamp":1792812811400,"version":"4.5.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Pneumococcal conjugate vaccine (PCV) has reduced the burden of pneumococcal disease by the near elimination of vaccine serotypes from countries giving a booster dose at &amp;gt;9 months of life. Herd protection, induced by interruption of pneumococcal vaccine type transmission has protected children too young to be immunized, children and adults with underlying risk conditions for invasive pneumococcal disease, and the elderly. PCV has rolled out in most poor countries, but millions of children remain un-immunized especially in middle income countries because of cost constraints. These are being met by considering fewer doses to maintain herd protection, and support for more affordable vaccine from developing country manufacturers. While 3rd generation PCV\u2019s with potential inclusion of 20+ serotypes are close to market in adults, it will be their introduction into childhood immunization and herd protection that is most likely to maximize the public health benefits of these vaccines.<\/jats:p>","DOI":"10.1093\/infdis\/jiaa535","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T19:08:09Z","timestamp":1597950489000},"page":"S352-S359","source":"Crossref","is-referenced-by-count":59,"title":["Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe"],"prefix":"10.1093","volume":"224","author":[{"given":"Gail L","family":"Rodgers","sequence":"first","affiliation":[{"name":"Bill & Melinda Gates Foundation, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia G","family":"Whitney","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health and Emory Global Health Institute, Emory University, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith P","family":"Klugman","sequence":"additional","affiliation":[{"name":"Bill & Melinda Gates Foundation, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"2021093008010259400_CIT0019","first-page":"184","article-title":"Prevention of pneumococcal pneumonia by vaccination","volume":"89","author":"Austrian","year":"1976","journal-title":"Trans Assoc Am Physicians"},{"key":"2021093008010259400_CIT0022","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente vaccine study center group","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"2021093008010259400_CIT0024","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0140-6736(05)71876-6","article-title":"Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial","volume":"365","author":"Cutts","year":"2005","journal-title":"Lancet"},{"key":"2021093008010259400_CIT0025","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMoa035060","article-title":"A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection","volume":"349","author":"Klugman","year":"2003","journal-title":"N Engl J Med"},{"key":"2021093008010259400_CIT0027","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nm1077","article-title":"A role for Streptococcus pneumoniae in virus-associated pneumonia","volume":"10","author":"Madhi","year":"2004","journal-title":"Nat Med"},{"key":"2021093008010259400_CIT0035","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0140-6736(12)61854-6","article-title":"Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial","volume":"381","author":"Palmu","year":"2013","journal-title":"Lancet"},{"key":"2021093008010259400_CIT0036","doi-asserted-by":"crossref","first-page":"e1001657","DOI":"10.1371\/journal.pmed.1001657","article-title":"Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial","volume":"11","author":"Tregnaghi","year":"2014","journal-title":"PLoS Med"},{"key":"2021093008010259400_CIT0041","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"2021093008010259400_CIT0048","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"key":"2021093008010259400_CIT0049","first-page":"e309","article-title":"Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States","volume":"2","author":"Simonsen","year":"2010","journal-title":"MBio"},{"key":"2021093008010259400_CIT0050","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1056\/NEJMoa1209165","article-title":"U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination","volume":"369","author":"Griffin","year":"2013","journal-title":"N Engl J Med"},{"key":"2021093008010259400_CIT0058","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1401914","article-title":"Effects of vaccination on invasive pneumococcal disease in South Africa","volume":"371","author":"von Gottberg","year":"2014","journal-title":"N Engl J Med"},{"key":"2021093008010259400_CIT0059","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/S0140-6736(18)33005-8","article-title":"Impact of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study","volume":"393","author":"Hammitt","year":"2019","journal-title":"Lancet"},{"key":"2021093008010259400_CIT0062","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1473-3099(13)70338-4","article-title":"Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial","volume":"14","author":"Palmu","year":"2014","journal-title":"Lancet Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/224\/Supplement_4\/S352\/40481508\/jiaa535.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/224\/Supplement_4\/S352\/40481508\/jiaa535.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T08:02:02Z","timestamp":1632988922000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/224\/Supplement_4\/S352\/6378090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":14,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2021,9,30]]},"published-print":{"date-parts":[[2021,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa535","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,9,30]]}}}